EP O173648 3, 1986 EP O173663 3, 1986 JP O9-110722* 4f1987 WO WO 97/44019 11,
1997 WO WO 98, 03529 1, 1998 WO WO 98.28445 7, 1998 WO WO 99/O7855 8, 1998 WO …

The present invention provides an edible composition for oral delivery of an active agent
such as a retinide. The composition comprises, in the form of a dry flowable powder:(a) an …

Pharmaceutical compositions and methods of treating ulcerating diseases, burns, and
related conditions are disclosed. The methods include administering to a host in need of …

Compositions and methods of using an MT103 family member, wherein MT103 is the
chemical N, N-dicyclohexyl-(1S)-isoborneol-10-sulfonamide. Uses of the compositions …

The present invention relates to compositions and methods for prevention and treatment of
ocular diseases and condi tions characterized by aberrant fibrogenesis or scarring …

USPC............ 424/1.29, 424/502.424/93; 424/96 (HPR) in the form of lipid nanoparticles,
solid dispersions 264/9: 514/613; 977/773; 977/797; 977/906 and emulsions are disclosed …

0003. The following description includes information that may be useful in understanding the
present invention. It is not an admission that any such information is prior art, or relevant, to …

2016-12-30 Assigned to ATHYRIUM OPPORTUNITIES II ACQUISITION LP, AS
ADMINISTRATIVE AGENT reassignment ATHYRIUM OPPORTUNITIES II ACQUISITION LP …

2009-09-09 Assigned to LPATH, INC. reassignment LPATH, INC. ASSIGNMENT OF
ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GARLAND …

Compositions and methods for producing monoclonal anti bodies and their derivatives
reactive against bioactive lipid targets are described. These compositions include …